Final US Army Phase 2 Platelet Results
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Vitrafy Life Sciences Ltd. announces the final results of its Phase II in-vitro study on platelet cryopreservation conducted with the US Army Institute of Surgical Research, highlighting successful outcomes across all tested protocols. The study demonstrated that the no-wash protocol significantly outperformed existing standards, achieving high post-thaw recovery and functionality of platelets. These results position Vitrafy to fill a market gap for cryopreserved platelets, validated by independent military research. The company plans to pursue FDA registration and present findings at international conferences.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vitrafy Life Sciences Ltd. on 6ix
Earlier from Vitrafy Life Sciences
- Q3 FY26 Quarterly Activities Report and Appendix 4C
- USAISR Completes Phase 2 Platelet Study
- FY26 Half Year Results Presentation
- FY26 Appendix 4D and Half Year Report
- Q2 FY26 Quarterly Activities Report and Appendix 4C
Later from Vitrafy Life Sciences
- Phase 2 USAISR Platelet Results Investor Presentation
- Vitrafy enters a partnership with Vitalant Innovation Center
- Trading Halt
- Vitrafy Equity Raising Presentation
- Vitrafy Placement Completion and SPP Announcement
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences